RxDoctor Payments DataLook up a doctor →

Richard Kirkpatrick, MD

Internal Medicine · Longview, WANPI 1851377030

Payments from drug & device makers

$18,712in general payments, 2019–2025

Across 1,005 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novartis$1K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$981
  • Lilly USA, LLC$858
  • GSK$652
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca100$2,712
Novartis63$1,244
Boehringer Ingelheim52$1,018
Novo Nordisk56$981
Lilly USA, LLC48$858
GSK50$652
Amarin Pharma, Inc.45$624
AbbVie(2 entities)37$622
Johnson & Johnson35$563
Sunovion Pharmaceuticals Inc.35$532
E.r. Squibb & Sons, L.L.C.35$529
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC28$446
Esperion Therapeutics, Inc.26$437
Grifols USA, LLC34$417
Lundbeck LLC18$405
Abbott9$373
Xeris Pharmaceuticals, Inc.13$360
Sanofi-aventis U.S. LLC19$333
Mylan Specialty L.p.18$306
Bayer15$306
Merck18$268
Pfizer12$256
Takeda Pharmaceuticals U.S.A., Inc.14$229
Otsuka America Pharmaceutical, Inc.12$215
Daiichi Sankyo Inc.9$182
Exact Sciences8$176
Actelion Pharmaceuticals US, Inc.7$160
Philips North America LLC12$158
Regeneron Healthcare Solutions, Inc.8$152
Corcept Therapeutics7$151
Amgen7$148
Astellas Pharma US Inc7$146
Boston Scientific8$138
Axsome Therapeutics, Inc.5$133
Impel Pharmaceuticals Inc.8$126
Gilead5$110
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$97
Electromed, Inc.6$95
Edwards Lifesciences3$94
Radius Health, Inc.5$90
Sumitomo Pharma America, Inc.4$79
Nevro Corp.4$78
Impulse Dynamics (USA) Inc.8$78
Teva Pharmaceuticals USA, Inc.4$75
Arbor Pharmaceuticals, Inc.5$71
Baxter Healthcare3$69
Kowa Pharmaceuticals America, Inc.4$68
Dexcom, Inc.3$67
Insulet Corporation3$67
Scilex Pharmaceuticals Inc.4$62
Vertex3$58
Eisai Inc.3$55
Phathom Pharmaceuticals, Inc.2$55
Lexicon Pharmaceuticals, Inc.3$50
Biodelivery Sciences International, Inc.4$48
Azurity Pharmaceuticals, Inc.3$46
Upsher-smith Laboratories LLC2$45
Smith+Nephew3$45
Bridgebio Pharma, Inc.2$45
Paratek Pharmaceuticals, Inc.2$44

How this compares

$18,712 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington →

Medicare billing

Part B allowed, 2024
$654,996
Medicare patients
932
Services billed
36,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Longview

See the full list for Washington →

Where these figures come from

Is this you, or does something look wrong? →